2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

940 Comparative outcomes of active monitoring in high-risk smoldering multiple myeloma: Randomized aquila study versus real-world SPARK study

Maria-Victoria Mateos Jr, MD, PhD, Mamta Garg, MD, FRCP, FRCPath2, Thomas Chalopin Jr, MD3, Sandra Ketzler-Henkel4, Ido Lapidot5, Julien Thevenon6, Nichola Erler-Yates, MsC Epi7, Lada Mitchell8, Jozefien Buyze9, Francesca Gay, MD, PhD10
1 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
2 Leicester Royal Infirmary, Leicester, United Kingdom
3 Centre Hospitalier Universitaire de Tours, Tours, France
4 Practice for Hematology and Oncology, Dortmund, Germany
5 J-C Health Care Ltd., Kibbutz Shefayim, Israel
6 Medical Affairs, Janssen Pharmaceuticals, Issy-les-Moulineaux, France
7 Janssen-Cilag GmbH, Neuss, Germany
8 J&J, Allschwil, Switzerland
9 Janssen Pharmaceutica NV, Beerse, Belgium
10 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Background

Smoldering multiple myeloma (SMM) is an asymptomatic precursor plasma cell disorder with variable risk of progression to active multiple myeloma (MM). Current management consists of active monitoring, with treatment typically initiated only after a myeloma-defining event occurs. Daratumumab monotherapy was recently approved for high-risk SMM based on AQUILA, a randomized, interventional phase 3 study. However, limited data are available comparing the AQUILA active-monitoring arm with real-world patients (pts) meeting the same high-risk SMM definition. SPARK is a retrospective real-world study describing the characteristics and outcomes of pts with SMM. In this study we compared outcomes between the AQUILA active-monitoring arm and those observed in the real-world setting in SPARK.

Methods

Matching-Adjusted Indirect Comparison (MAIC) methodology was used to estimate the hazard ratio (HR) of progression-free survival (PFS) between the two studies adjusted for differences in baseline characteristics. Data sources for the MAIC were derived from aggregate-level data (AGD) from the active monitoring arm in AQUILA and individual patient-level data (IPD) from SPARK patients that met the definition of high-risk according to the AQUILA criteria. The final poster presentation will also include the application of propensity score methodologies to further strengthen the indirect comparison.

Results

SPARK included 408 real-world SMM pts from 5 different countries, of which 194 were high-risk according to the AQUILA criteria. Median follow-up was 62.3 months. AQUILA included 390 high-risk SMM patients, 194 in the interventional arm and 196 in the active monitoring arm. Median follow-up was 65.2 months. For this analysis, the AQUILA active monitoring arm contributed 196 high-risk patients, and SPARK contributed 194 high risk patients according to AQUILA criteria. MAIC yielded an effective sample size of 185 patients in SPARK, which indicates sufficient overlap between both populations. The median time to MM/death (PFS) in the active monitoring arm of AQUILA was 48.0 months (95% CI: 36.0 – NA). The median PFS in SPARK high-risk pts according to AQUILA criteria was 53.8 months (95% CI: 44.2 – 70.6) before weighting and 58.4 months (95% CI: 45.8 – 70.6) after weighting.

Although the median PFS in SPARK remained numerically longer, the hazard ratio after weighting was 0.93 (95% CI: 0.67 – 1.29), resulting in no meaningful PFS difference between AQUILA and SPARK. The MAIC analysis demonstrated good covariate balance and substantial population overlap, indicating that the SPARK high-risk cohort provides a representative match to the AQUILA active monitoring population.

In SPARK, 80/194 (41.2%) high-risk pts progressed to MM, 46 pts (57.5%) met CRAB criteria, 24 pts (30%) met SLiM criteria, and the rest with unknown type of progression. In the AQUILA active monitoring arm 94/196 pts (48%) progressed to MM, 34 (36%) met CRAB criteria and 65 pts (69.1%) met SLiM criteria. For both SPARK and AQUILA, bone lesions were the most common CRAB event; 29 (36.3%) and 18 (19.1%), respectively. In SPARK 4 pts (5%) developed renal failure vs none in the AQUILA active monitoring arm.

Conclusions

Our analysis confirms the comparability of outcomes between high-risk SMM patients in the active monitoring arm of the randomized AQUILA study and real-world non-interventional trial patients meeting the same high-risk definition in SPARK. Although time to MM/death was similar between AQUILA and real-world SPARK, the type of MM-defining event differed significantly. In AQUILA most MM progressions were SLiM events, while in real-world SPARK most progressions were CRAB events, resulting in over 1.5 fold higher incidence of CRAB events versus the AQUILA active-monitoring arm. These findings confirm prior evidence that in real-world practice without protocol-mandated monitoring schedules, progression to MM may be more likely to be detected only after CRAB events occur, potentially increasing the risk of organ damage in high-risk SMM patients.

Maria-Victoria Mateos Jr, MD, PhD: AbbVie - Honoraria; GSK - Honoraria; Roche - Honoraria; Johnson&Johnson - Honoraria; Takeda - Honoraria; Sanofi - Honoraria; Janssen - Honoraria; Oncopeptides - Honoraria; Amgen - Honoraria; Stemline Menarini - Honoraria; Kite - Honoraria; BMS-Celgene - Honoraria; Regeneron - Honoraria; Pfizer - Honoraria; BMS - Honoraria; Eli Lilly and Company - Honoraria; Sanofi - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Johnson&Johnson - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Stemline Menarini - Consultancy (Includes expert testimony); Eli Lilly and Company - Consultancy (Includes expert testimony)